May 18, 2020 / 5:11 AM / 14 days ago

BRIEF-Vifor Pharma: VFMCRP And Chemocentryx Announce Topline Data From Phase-II Lumina-1 Trial Of CCX140 In Focal Segmental Glomerulosclerosis

May 18 (Reuters) - VIFOR PHARMA AG:

* VFMCRP AND CHEMOCENTRYX ANNOUNCE TOPLINE DATA FROM PHASE-II LUMINA-1 TRIAL OF CCX140 IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below